Literature DB >> 6859224

Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro.

C D Bucana, L C Hoyer, A J Schroit, E Kleinerman, I J Fidler.   

Abstract

Human blood monocytes were activated to become tumoricidal by incubation with liposomes containing muramyl tripeptide-phosphatidylethanolamine, a lipophilic derivative of muramyl dipeptide. The interaction of both tumoricidal and control monocytes with target melanoma cells was analyzed by means of light microscopy and scanning and transmission electron microscopy. The authors found increased clustering around the melanoma cells by tumoricidal monocytes as compared with the control monocytes. The initial clustering of the tumoricidal monocytes around the tumor cells was followed by the establishment of numerous focal points of contact (binding), some of which actually exhibited areas of discontinuous membrane, a finding confirmed by stereophotography. By 24-48 hours of cocultivation, many of the target cells exhibited zones of vacuolation in the immediate vicinity of the tumoricidal monocytes, suggesting target cell damage. (This finding was confirmed by time-course cytotoxicity assays.) The authors conclude that tumor cell lysis mediated by activated human blood monocytes occurs as the final step in a process that includes the establishment of a direct cell-cell contact, damage to the target cell membrane, and the development of areas of vacuolation in the target cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6859224      PMCID: PMC1916313     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Immune cytolysis of mouse macrophages in vitro.

Authors:  R Gallily; Z Ben-Ishay
Journal:  J Reticuloendothel Soc       Date:  1975-07

2.  Augmentation of tumoricidal activity of human monocytes and macrophages by lymphokines.

Authors:  A Mantovani; J H Dean; T R Jerrells; R B Herberman
Journal:  Int J Cancer       Date:  1980-06-15       Impact factor: 7.396

3.  The destruction of allogeneic tumour cells by peritoneal macrophages from immune mice: purification of lytic effector cells.

Authors:  M D Boyle; M G Ormerod
Journal:  Cell Immunol       Date:  1975-05       Impact factor: 4.868

4.  Ultrastructural studies of histiocyte-tumor cell interactions during tumor regression after intralesional injection of Mycobacterium bovis.

Authors:  M J Snodgrass; M G Hanna
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

5.  Heterocytolysis by macrophages activated by bacillus Calmette-Guérin: lysosome exocytosis into tumor cells.

Authors:  J B Hibbs
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

6.  Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages.

Authors:  J B Hibbs
Journal:  J Natl Cancer Inst       Date:  1974-11       Impact factor: 13.506

7.  The ultrastructure of sarcoma I cells and immune macrophages during their interaction in the peritoneal cavities of immune C57BL-6 mice.

Authors:  V C Chambers; R S Weiser
Journal:  Cancer Res       Date:  1972-02       Impact factor: 12.701

8.  Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

9.  The activation of mononuclear phagocytes in vitro: immunologically mediated enhancement.

Authors:  D O Adams; J L Biesecker; L G Koss
Journal:  J Reticuloendothel Soc       Date:  1973-12

10.  The in vitro induction and release of a cell toxin by immune C57B1-6 mouse peritoneal macrophages.

Authors:  J J Kramer; G A Granger
Journal:  Cell Immunol       Date:  1972-01       Impact factor: 4.868

View more
  15 in total

1.  Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system.

Authors:  H Sakai; H Horinouchi; K Tomiyama; E Ikeda; S Takeoka; K Kobayashi; E Tsuchida
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Isolation and characterization of antigen-presenting dendritic cells from the mouse intestinal lamina propria.

Authors:  P Pavli; C E Woodhams; W F Doe; D A Hume
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

Review 3.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

4.  Human monocytes selectively bind to cells expressing the tumorigenic phenotype.

Authors:  H Shimizu; D Wyatt; R D Knowles; C D Bucana; E J Stanbridge; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation.

Authors:  J Connor; C Bucana; I J Fidler; A J Schroit
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Killed Escherichia coli stimulates macrophage-mediated alterations in hepatocellular function during in vitro coculture: a mechanism of altered liver function in sepsis.

Authors:  M A West; G A Keller; F B Cerra; R L Simmons
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

Review 7.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 8.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

9.  Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.

Authors:  E S Kleinerman; R H Wiltrout; R Zicht; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.